Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system

被引:43
作者
Sawchuk, RJ
Yang, Z
机构
[1] Univ Minnesota, Coll Pharm, Dept Pharmaceut, Minneapolis, MN 55455 USA
[2] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Metab & Pharmacokinet, Wallingford, CT 06492 USA
关键词
AIDS; dementia; brain; uptake; efflux; transport; pharmacokinetics; nucleoside analog; non-nucleoside inhibitor; protease inhibitor;
D O I
10.1016/S0169-409X(99)00017-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The distribution of currently available anti-MN drugs into the CNS is reviewed with a focus on transport mechanisms. Among these drugs, nucleoside analogs an most well studied for their CNS distribution. The average reported values of the CSF/plasma steady-state concentration or corresponding AUC ratios are 0.23 (AZT), 0.06 (ddI), 0.04 (ddC), 0.49 (d4T), and 0.08 (3TC). Active efflux transport out of the CNS appears to be a predominant mechanism limiting nucleoside access to the CNS, although poor penetration may contribute to some extent for some polar nucleosides. The nature of the efflux pump for these drugs is speculated to be MRP-like transporter(s) in blood-brain and blood-CSF barriers. For non-nucleoside and protease inhibitors, much research remains to be done on the extent, time course, and mechanisms of their CNS distribution. The CNS penetration of some protease inhibitors is restricted by P-glycoprotein. A better understanding of transport mechanisms of anti-HIV drugs in the CNS is essential to develop approaches to enhance CNS delivery of available drugs and to identify new drugs less subject to active efflux transporter(s) in the CNS. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:5 / 31
页数:27
相关论文
共 160 条
[71]  
KLINE MW, 1995, PEDIATRICS, V96, P247
[72]  
Kool M, 1997, CANCER RES, V57, P3537
[73]  
Kusuhara H, 1998, J PHARMACOL EXP THER, V285, P1260
[74]   HIV WITH REDUCED SENSITIVITY TO ZIDOVUDINE (AZT) ISOLATED DURING PROLONGED THERAPY [J].
LARDER, BA ;
DARBY, G ;
RICHMAN, DD .
SCIENCE, 1989, 243 (4899) :1731-1734
[75]  
Lee K, 1998, CANCER RES, V58, P2741
[76]  
Lin JH, 1996, DRUG METAB DISPOS, V24, P1111
[77]  
Lipton SA, 1997, SCIENCE, V276, P1629
[78]  
LITTLE R, 1990, J BIOPHARM SCI, V1, P1
[79]   PENETRATION OF ZIDOVUDINE AND 3'-FLUORO-3'-DEOXYTHYMIDINE INTO THE BRAIN, MUSCLE-TISSUE, AND VEINS IN CYNOMOLGUS MONKEYS - RELATION TO ANTIVIRAL ACTION [J].
LJUNGDAHLSTAHLE, E ;
GUZENDA, E ;
BOTTIGER, D ;
WAHREN, B ;
OBERG, B ;
STAHLE, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (11) :2418-2422
[80]   COMPARATIVE PHARMACOKINETICS OF 2 PRODRUGS OF ZIDOVUDINE IN RABBITS - ENHANCED LEVELS OF ZIDOVUDINE IN BRAIN-TISSUE [J].
LUPIA, RH ;
FERENCZ, N ;
LERTORA, JJL ;
AGGARWAL, SK ;
GEORGE, WJ ;
AGRAWAL, KC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (04) :818-824